Indeed, dual targeting of HER2 and HER2/HER3 dimerization with trastuzumab and pertuzumab results in enhanced tumor inhibitory effects in mouse xenograft models, and significantly prolongs progression-free survival in HER2-overexpressing breast cancer [11, 49, 50]. Here, ERBB2 is linked to neoplasm.